Figure 3.Efficacy of DUBRI in predicting immunotherapy outcome. (A, B) Differences in expression levels of common immune checkpoints between high/low DUBRI groups. (C) Difference between TIDE score, Dysfunction, MSI and Exclusion between high/DUBRI and low DUBRI groups. (D) Differences in IPS scores between high/low DUBRI groups.
